The State-Level Battle for 340B
While federal 340B policy gets the headlines, the most consequential changes are happening at the state level. As of mid-2026, multiple states have enacted or introduced laws addressing 340B contract pharmacy access, manufacturer restrictions, or covered entity protections.
This creates a compliance challenge that didn’t exist five years ago. A covered entity operating in multiple states, or a contract pharmacy chain with national presence, must now track and comply with a patchwork of state-specific requirements that vary in scope, enforcement mechanism, and effective date.
The days of managing 340B compliance as a purely federal exercise are over.
States That Protect Contract Pharmacy Access
At least eight states have enacted laws that specifically prohibit or restrict manufacturers from imposing conditions on 340B pricing for drugs dispensed through contract pharmacies. These laws take several forms.
Some states, like Arkansas, Louisiana, and West Virginia, passed broad anti-discrimination statutes that prohibit manufacturers from denying 340B pricing to covered entities that use contract pharmacies. Other states, like Minnesota and Oregon, focused specifically on prohibiting manufacturers from requiring covered entities to submit claims-level data to third-party platforms as a condition of receiving 340B pricing.
The legal landscape is fluid. Several of these state laws face ongoing litigation from PhRMA and individual manufacturers challenging them on preemption, Commerce Clause, and First Amendment grounds. Covered entities should monitor the status of litigation in each state where they operate contract pharmacies.
State Reporting and Transparency Requirements
A growing number of states have added 340B-specific reporting requirements. These are distinct from the federal CMS Drug Acquisition Cost Survey and create additional compliance obligations.
Some states require covered entities to report how 340B savings are used. Others require disclosure of contract pharmacy arrangements, including the fees paid to contract pharmacies and the volume of prescriptions dispensed through each location.
States with transparency requirements include Washington, Colorado, and Virginia, among others. The specifics vary, but the trend is clear: state legislators want data on how 340B savings flow through the healthcare system, and they’re willing to legislate to get it.
For covered entities, this means building reporting infrastructure that can produce state-specific disclosures on a timeline that may not align with federal reporting cycles.
Compliance Strategy for Multi-State Operations
Organizations with 340B operations in multiple states need a structured compliance approach.
First, map your state exposure. Identify every state where you have a covered entity site, a contract pharmacy, or a patient population that generates 340B-eligible prescriptions. For each state, document the applicable state 340B laws, their effective dates, and their requirements.
Second, centralize your monitoring. State legislatures move fast. Bills can move from introduction to enactment in a single session. Assign responsibility for tracking 340B-related legislation in your relevant states. The 340B Health association provides legislative tracking, as do several commercial compliance platforms.
Third, standardize where possible, customize where required. Your core 340B policies and procedures should be consistent across all locations. Layer state-specific requirements on top as addenda rather than rewriting your entire compliance program for each state.
Fourth, coordinate with your contract pharmacy partners. If your contract pharmacy operates in a state with anti-discrimination protections, they may have different leverage with manufacturers than in states without such protections. Your contract pharmacy agreements should address state-specific compliance obligations for both parties.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Nexwell Health Partners provides management services, telehealth solutions, and compliance support for safety-net hospitals, FQHCs, and specialty practices. Contact us to schedule a consultation.
Sources